Epigenetic activities of flavonoids in the prevention and treatment of cancer by Christian Busch et al.
Busch et al. Clinical Epigenetics  (2015) 7:64 
DOI 10.1186/s13148-015-0095-zREVIEW Open AccessEpigenetic activities of flavonoids in the
prevention and treatment of cancer
Christian Busch1, Markus Burkard1,2, Christian Leischner2, Ulrich M. Lauer2, Jan Frank3 and Sascha Venturelli2*Abstract
Aberrant epigenetic modifications are described in an increasing number of pathological conditions, including
neurodegenerative diseases, cardiovascular diseases, diabetes mellitus type 2, obesity and cancer. The general
reversibility of epigenetic changes makes them an attractive and promising target e.g. in the treatment of cancer.
Thus, a growing number of epigenetically active compounds are currently tested in clinical trials for their
therapeutic potential. Interestingly, many phytochemicals present in plant foods, particularly flavonoids, are
suggested to be able to alter epigenetic cellular mechanisms. Flavonoids are natural phenol compounds that form
a large group of secondary plant metabolites with interesting biological activities. They can be categorized into six
major subclasses, which display diverse properties affecting the two best characterized epigenetic mechanisms:
modulation of the DNA methylation status and histone acetylation. High dietary flavonoid intake has strongly been
suggested to reduce the risk of numerous cancer entities in a large body of epidemiological studies. Established
health-promoting effects of diets rich in fruit and vegetables are faced by efforts to use purified flavonoids as
supplements or pharmaceuticals, whereupon data on the latter applications remain controversial. The purpose of
this review is to give an overview of current research on flavonoids to further elucidate their potential in cancer
prevention and therapy, thereby focusing on their distinct epigenetic activities.
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Cancer is one of the main causes of death worldwide, and
cancer mortality is expected to be more than double in
the next 20–40 years [1, 2]. In general, tumour growth is
associated with both epigenetic and genetic aberrations
resulting in altered gene expression [3]. Furthermore, epi-
genetic deregulation already occurs during early phases of
neoplastic development and was suggested to have a com-
parable influence on promoting malignant transformation
and subsequent tumour growth as genetic mutations [4].
For instance, DNA hypermethylation of promoter regions
can cause binding of methyl DNA binding proteins, essen-
tial for gene inactivation (mainly of tumour suppressor
genes), and global DNA hypomethylation is associated
with chromosomal instability [5–7]. Both can be measured
in cancer cells, and chromosomal instability is recognized
as one of the “hallmarks of cancer” [7, 8]. Additionally, an* Correspondence: sascha.venturelli@med.uni-tuebingen.de
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creativecommons.org/publicdomain/zero/1.0/altered histone acetylation status can modulate activation
or silencing of tumour suppressor genes [9]. Despite the
observation that epigenetic changes are heritable in som-
atic cells and epimutations are rare in non-transformed
cells or healthy tissues, it is of interest to note that epigen-
etic modifications are potentially reversible. Therefore, tar-
geting epigenetic mechanisms is a promising approach for
cancer prevention and/or therapy and also for other dis-
eases [5, 10, 11]. According to current estimates, cancer is
in, at least, 30–40 % of the cases preventable with ap-
propriate or balanced food and nutrition, regular physical
activity and avoidance of obesity [2]. To date, multiple bio-
logically active food components are strongly suggested to
have protective potential against cancer formation, even
though these effects are not yet firmly established for the
majority of these compounds [12]. Examples are methyl-
group donors, selenium, fatty acids, and phytochemicals,
such as flavonoids, retinoids, isothiocyanates, and allyl
compounds [2].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Even though the cells of an organism share the same set
of genes, they are differentiated into diverse types of
cells and tissues individually characterized by their own
biochemical capabilities, (functional) morphology, and
gene expression profile. Thus, there is a need for highly
ordered regulatory mechanisms determining the fate of
each cell. Epigenetic changes are heritable modifications
affecting gene expression without causing alterations in
the nucleotide sequence itself [13]. The most common
epigenetic modifications (Fig. 1) are changes in the DNA
methylation pattern, posttranslational histone modifica-
tions, and variations in the expression of non-coding
microRNA (miRNA). DNA methylation is catalysed by
DNA methyltransferases (DNMT), and histone acetylation
state is adjusted by opposing activities of histone acetyl-
transferases (HAT) and histone deacetylases (HDAC). His-
tone methylation is regulated by histone methyltransferases
(HMT) and histone demethylases (HDM) [4]. Of note, ab-
errant expression or activity of HMT [14, 15] and HDM
[16] has also been associated with cancer development [4].
MiRNA is another epigenetic regulatory system that
post-transcriptionally influences the regulation of geneFig. 1 Important epigenetic modifications known to regulate gene express
methyltransferases (DNMT) represses gene activity. Posttranslational covalen
in the “histone tail” also influence gene expression in different ways. b Hist
usually correlated to increased gene activity, whereas histone deacetylation
gene expression, even though histone hyperacetylation not always matche
demethylation by histone methyltransferases (HMT) and histone demethyla
activity depending on number and position of methyl groups. d Histone u
allows access of enzymes involved in transcription. e Histone phosphorylat
increased gene expression, and it is also involved in DNA damage respons
is considered to be a signal for the release of histone H1 from chromatin. I
epigenetic marks by writer enzymes (e.g. DNMT, HMT, HAT) and the remov
as well as epigenetic reader enzymes (not shown in this figure)expression and is important for RNA-silencing [17, 18].
Epigenetic changes have been reported during cancer de-
velopment and are found in genes involved in cell differ-
entiation, proliferation, and survival or apoptosis [4, 19].
CpG dinucleotides (cytosine-phosphate-guanine; cytosine
nucleotide followed by a guanine nucleotide) are prone to
methylation in the human genome. About 70 % of the
CpG are methylated (mostly CpG dinucleotides, which are
dispersed throughout the genome), whereas a minority of
CpG residues is unmethylated (mostly CpG clusters also
known as CpG islands, which are mainly located at the 5′
side of genes) [5, 12]. Methylation of CpG islands plays an
important role in regulation of gene expression [4, 19].
Approximately 70 % of CpG islands in the human genome
are resistant to de novo methylation caused by overexpres-
sion of DNMT1 [20], and even though 50 % of all mam-
malian genes exhibit CpG islands, only a minority is prone
to silencing by hypermethylation [5, 20, 21]. Human
DNMT (DNMT1, DNMT2, DNMT3a and DNMT3b)
specifically methylate the C5 position of cytosine in CpG
dinucleotides [5, 22]. DNMT1 maintains DNA methyla-
tion patterns, whereas DNMT2 shows only weak methyla-
tion activity [23]. DNMT3a and DNMT3b are responsibleion. a DNA methylation of CpG islands in promoter regions by DNA
t histone modifications of lysine (K), arginine (R) or serine (S) residues
one acetylation (Ac) catalysed by histone acetyltransferases (HAT) is
caused by histone deacetylases (HDAC) is considered to decrease
s regions of increased gene activity. c Histone methylation (Me) and
ses (HDM) at lysine or arginine residues show different effects on gene
biquitinylation (Ub) at lysine residues alters histone structure and
ion (P) at distinct serine residues is known to be associated with
e and chromatin remodelling. Phosphorylation at linker histone (LH) H1
n general, epigenetic regulation depends on the addition of
al of these marks by epigenetic eraser enzymes (e.g. HDAC and HDM)
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genesis and other cell differentiation events [20, 23]. Most
cancer cells exhibit on the one hand a global DNA hypo-
methylation and on the other hand, simultaneously, a
DNA hypermethylation of specific promoter regions for
e.g. tumour suppressor genes or genes important for apop-
tosis [5, 6]. Malignantly transformed cells modify tran-
scription of genes by changes in the methylation of CpG
islands within gene promoter regions and/or by changing
posttranslational histone modifications like histone deace-
tylation as well as distinct histone methylation patterns
resulting in decreased gene transcription (Fig. 1). In cancer
cells, DNMT1 is both able to maintain DNA methylation
and to de novo-methylate DNA of tumour suppressor
genes [24]. However, aberrant DNA methylation is not
limited to cancer cells; abnormal DNMT expression is also
linked to various diseases including depression, anxiety
disorder, dementia, autism, cardiovascular diseases, obesity
and type 2 diabetes [25–30].
Histone proteins are present in eukaryotic nuclei,
where they facilitate the dense packing of DNA and thus
play an essential role in the dynamic accessibility of
DNA for transcription factors. In humans, there exist
two major histone families: the linker histone (LH) and
the core histones. Each histone subfamily comprises one
or more different variants. The core histones (two each
of H2A, H2B, H3, and H4) form an octameric stru-
cture called nucleosome, which is a basic element of
DNA packaging and consists of 146 base pair units of
DNA that are coiled around the octamer of such core
histone proteins [12]. The LH H1 binds to the nucleo-
some and the linker DNA helping to stabilize the chro-
matin fibre [31, 32]. Histone phosphorylation is mostly
associated with actively transcribed genes, but phosphor-
ylation of H1 is also considered to be an important sig-
nal for the release of the LH. The dynamic structure of
chromatin allows rapid changes in gene regulation [5].
Moreover, the N-termini of histone proteins contain
multiple lysine residues and are accessible to covalent
modifications such as acetylation, methylation, sumoyla-
tion, biotinylation, phosphorylation, glycosylation, and
ADP-ribosylation, thus allowing regulation of gene tran-
scription (Fig. 1) [4, 5, 33–36]. Chromatin consists of
nucleosome units connected by linker DNA, condensing
the volume of the genetic information in eukaryotes
[4, 37, 38]. Generally, two distinct states of chromatin
are distinguished [4, 38]: heterochromatin is densely com-
pacted and transcriptionally almost inactive; the de-
condensed euchromatin is only lightly packed, allowing
transcriptional activity. Gene expression is hence deter-
mined by interactions between DNA methylation, histone
modification, and nucleosome positioning influencing
chromatin structure. Presence of chromatin remodellers,
chromatin-associated proteins, and methyl DNA bindingproteins are also important for structural modification of
chromatin [4, 39, 40].
Histone acetylation is one of the most studied post-
translational histone modifications to date. Historically,
HAT were divided into two groups: type A exhibits a nu-
clear localization, whereas type B is distributed through-
out the cytoplasm and acetylates newly synthesized
proteins [5, 33]. To date, three main families of HAT
proteins are distinguished among others (MYST, GNAT,
and CBP/p300) [4]. Based on their sequence homology
to the enzymes found in yeast, HDAC are divided into
four classes [41–43]: class I, which comprises the HDAC
isoforms HDAC1, HDAC2, HDAC3, and HDAC8, is lo-
cated predominantly in the nucleus; class IIA, containing
HDAC4, HDAC5, HDAC7, and HDAC9 as well as class
IIB including HDAC6 and HDAC10 (HDAC6 with two
catalytic sites), preferentially shuttle between the nucleus
and the cytosol; class III are the nicotinamide adenine
dinucleotide (NAD+)-dependent sirtuins (SIRT1-7); and
class IV consists only of HDAC11, which has catalytic
residues in its active centre shared by class I and II
[5, 41, 44, 45]. Class I, II, and IV HDAC exhibit hom-
ology in both sequence and structure and require a zinc
ion for their catalytic activity. These three classes of
HDAC completely differ from the sirtuin family regard-
ing sequence and structure. Sirtuins were investigated
for their contribution to lifespan prolongation under cal-
oric restriction conditions in lower organisms [4, 46]. In
addition, sirtuins exert a variety of different effects on
DNA repair mechanisms, chromosomal integrity, cellu-
lar senescence, cell cycle progression, and transcriptional
activity of tumour-associated proteins such as p53, p73,
retinoblastoma protein (pRb), nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB), and the
FoxO family [4, 46–48]. Different HDAC isoforms are
frequently overexpressed in certain tumour entities,
whereas reduced levels of specific HDAC isoforms were
observed in some tumour types [4]. Therefore, it is still
a big issue that many HDAC inhibitors (HDACi) show
only little specificity among the different HDAC iso-
forms [49] and histone hyperacetylation does not neces-
sarily correlate with regions of increased gene expression
[36]. Nonetheless, HDACi seem to be promising cancer-
preventive and therapeutic agents capable to reactivate
tumour suppressor genes [50, 51]. Genomic instability
found in majority of cancer cells causes an increased
vulnerability against DNA damaging agents [50]. There-
fore, tumour cells might be more susceptible to exogen-
ous compounds causing oxidative stress by production
of reactive oxygen species than healthy tissue [52]. Note-
worthy, DNA and histone modifying enzymes are highly
dependent on essential metabolites such as acetyl-CoA,
iron, ketoglutarate, NAD+, and S-adenosyl methionine
(SAM) and rely on a stable cellular metabolic state [12].
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DNA methyltransferase inhibitors in clinical use for the
treatment of cancer
A number of DNMT inhibitors (DNMTi) are already in
clinical use or currently under investigation in clinical
trials. The pyrimidine nucleoside analogues azacitidine
(5-azacytidine, Vidaza®) and decitabine (5-aza-2′deoxycy-
tidine, Dacogen®) are approved by the US Food and Drug
Administration (FDA) for the treatment of myelodys-
plastic syndrome (MDS) and acute myeloid leukaemia
(AML) [4, 53, 54]. How DNMTi specifically affect cancer
cells is currently under intensive investigation. The ribo-
nucleoside azacitidine is an analogue of cytosine, which
is important for DNA and RNA synthesis [55]. Azaciti-
dine incorporates into RNA and to a lesser extent into
DNA [56, 57]. Inclusion into RNA can subsequently
cause disassembly of polyribosomes [58, 59], thus dis-
turbing tRNA and ultimately protein synthesis, while
incorporation into DNA induces covalent binding to
DNMT, thus preventing DNA methylation and very
likely replication. Noteworthy, the unspecific disruption
of intracellular protein biosynthesis is probably respon-
sible for the high toxicity of azacitidine. In contrast, dec-
itabine is exclusively incorporated into DNA [60], acting
as a DNMTi due to covalent binding [57, 61]. Decitabine
is supposed to be a more potent DNMTi in vitro than
other nucleoside and non-nucleoside inhibitors [62, 63].
Clinical efficacy in the treatment of AML, acute lym-
phocytic leukaemia (ALL), chronic myeloid leukaemia
(CML), and chronic myelomonocytic leukaemia (CMML)
is suggested to be caused by DNA demethylating activity
of decitabine [64]. Generally, the identification of de-
methylation events caused by the use of DNMTi in vivo
is challenging and shows substantial differences in pa-
tients [57, 65]. The majority of studies on humans have
investigated the methylation state of the p15 tumour
suppressor gene, which is often hypermethylated in
MDS and AML. Unfortunately, demethylation and
re-expression of p15 could not be correlated to the clinical
responses of treated patients [57]. Limitations for the
clinical application of the nucleoside inhibitors are their
cytotoxicity (especially azacitidine), low drug stability,
poor oral availability, and rapid elimination [5, 10]. Al-
though several nucleoside inhibitors have demonstrated
anticancer properties in preclinical models and are
under clinical investigation, so far, partly due to their
toxicity, only azacitidine and decitabine have been ap-
proved by the FDA for the treatment of cancer. Distinct
flavonoids and other natural compounds like vitamin C
(at high doses such as 8 mmol/L, achievable in patients
by i.v. administration) [66] are known to act as DNMTi
either directly by interaction with the active site of these
enzymes or by indirect mechanisms. Therefore, flavo-
noids and their derivatives may serve as novel andalternative compounds with DNMTi activity for the pre-
vention and treatment of cancer.
Histone deacetylase inhibitors in clinical use for the
treatment of cancer
HDACi can be divided into different chemical classes.
HDACi share a metal binding domain enabling them to
compete with substrates for the required Zn2+-interaction
in the binding pocket of the enzymes [5, 33]. Known
HDACi are short chain fatty acids (e.g. sodium butyrate
and valproate) with in vitro IC50 in the millimolar range,
the very potent hydroxamic acids (e.g. trichostatin A
(TSA) and vorinostat) displaying IC50 in nano- to micromo-
lar range, benzamides (e.g. MS-275 and N-acetyldinaline),
and cyclic tetrapeptides/epoxides (e.g. trapoxin and ro-
midepsin) with IC50 in the nanomolar range [44, 67].
Noteworthy, some HDACi were isolated from natural
sources or developed from plant-derived compounds.
TSA is an antibiotic isolated from Streptomyces sp. with
fungicidal properties and one of the most potent HDACi
known to date with an IC50 in the low nanomolar range.
Its production is expensive and TSA displays several un-
desirable side effects [5, 67]. Vorinostat and romidepsin
progressed to clinical trials and are the first HDACi ap-
proved by the FDA for the treatment of cutaneous T cell
lymphoma. Vorinostat is a chemical compound suitable
for docking into the active site of HDAC of classes I, II
and IV [5, 68]. Romidepsin is a natural product obtained
from Chromobacterium violaceum and can be considered
as a prodrug [51]. More recently, the HDACi belinostat
and panobinostat were FDA approved. Belinostat is used
in the treatment of relapsed or refractory peripheral T cell
lymphoma, and panobinostat is available for the treatment
of recurrent multiple myeloma in combination with borte-
zomib and dexamethasone [69, 70]. Despite the promising
potential of HDACi in the treatment of some cancer en-
tities, there have also been issues concerning low specifi-
city to the different HDAC isoforms and adverse effects
[36]. In this regard, some promising inhibitors like TSA
were not approved for the clinical use and an intensive
search for novel epigenetic drugs combined with the
evaluation in clinical trial is ongoing [71]. Interestingly,
some innocuous phytochemicals including flavonoids dis-
play a HDACi activity.
Flavonoids
Flavonoids are a large group of secondary plant metabo-
lites (also known as phytochemicals). More than 4000
different flavonoids are described so far [72]. Flavonoids
belong to the polyphenol family. The basic chemical
structure of flavonoids is the flavan backbone. It com-
prises two phenolic rings (named A and B) linked by an
oxygen-containing heterocycle (C) and is the structural











































Fig. 2 Chemical structures of flavonoid subclasses. The six flavonid subclasses include flavan-3-ols, flavonols, flavones, flavanones, isoflavones, and
anthocyanidins, which all feature a flavan backbone. The closely related chalcones (ring closure causes flavonoid formation) and flavonolignans
(complex flavonoids consisting of a flavonoid covalently bound to a lignan) are displayed as well (grey box)
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subclasses: flavan-3-ols (also known as flavanols or
catechins), flavonols, flavones, flavanones, isoflavones,
and anthocyanidins [48]. Variations in the saturation, hy-
droxylation and glycosylation of the rings are responsible
for the large number of individual compounds within
each of these subclasses. Flavonoids are widely distrib-
uted throughout the plant kingdom, where they function
as pigments, phytohormones, and protect against UV ra-
diation, insect pests, and plant diseases [73, 74]. Further-
more, flavonoids have been reported to exert a number
of biological activities in mammals, such as antibacterial,
antiviral, analgesic, antiallergic, hepatoprotective, cyto-
static, apoptotic, oestrogenic and anti-oestrogenic func-
tions, to name only a few [75–77]. These diverse
biological activities have been attributed to many mo-
lecular mechanisms, including the modulation of the ac-
tivities of phase I and II detoxification enzymes, direct
and indirect antioxidant activities [76, 78, 79], inhibition
of protein kinases, effects on cell cycle, modulation of
gene transcription, and epigenetic activities [5, 80]. The
described effects are important due to the presence of
these compounds in the human diet and their regular
ingestion. According to a French study, published by
Brat and colleagues, the total polyphenol intake from
fruit is about three times higher compared to that fromvegetables, based on the overall low polyphenol level in
vegetables [81]. The mean total daily polyphenol intake
of French adults is estimated to be 1193 ± 510 mg/day
[82]. The flavonoid intake of the Australian population
e.g. is estimated to be 454 mg/day with 92 % flavan-3-ols
[83]. The estimated mean daily total flavonoid intake in
US adults e.g. is described by Chun and coworkers with
189.7 mg/day, with a portion of 83.5 % from flavan-3-
ols, 7.6 % flavanones, 6.8 % flavonols, 1.6 % anthocyani-
dins, 0.8 % flavones, and 0.6 % isoflavones [84].
Epigenetic activities of flavonoids
Flavan-3-ols
Rich sources of flavan-3-ols are e.g. apples, grapes, wine,
cacao, and tea [72] (Fig. 2). Tea is the most widely con-
sumed beverage worldwide next to water [85, 86]. Green,
black, and oolong tea, which differ by their degree of fer-
mentation, are the most popular teas. Green tea leaves are
only dried and roasted, oolong tea is partially fermented,
and black tea extensively fermented [87–90]. All of
these teas contain varying amounts of e.g. (+)-catechin,
(−)-epicatechin (EC), (−)-epicatechin-3-gallate (ECG),
(−)-epigallocatechin (EGC), and (−)-epigallocatechin-3-
gallate (EGCG). The flavan-3-ol EGCG is the most
abundant flavonoid in green tea [5, 90, 91] (Fig. 3).
EGCG induces apoptosis (e.g. in HaCaT, L5178Y, and
Fig. 3 Chemical structures of flavonoids known to exert epigenetic activity. Flavan-3-ols: (+)-catechin and epigallocatechin-3-gallate; flavonols:
kaempferol, quercetin, myricetin, and fisetin; flavones: apigenin and luteolin; flavanones: hesperetin and naringenin; isoflavones: genistein and
daidzein; flavonolignan: silibinin
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cytes) [92] and cell cycle arrest in A-431 human epiderm-
oid carcinoma cells [92] while reducing oxidative stress
(e.g. metal ion chelation by vicinal dihydroxyl and trihy-
droxyl structures) and angiogenesis [87, 93]. EGCG was
further shown to inhibit DNMT activity by direct enzyme
interaction leading to decreased cellular concentrations of
5-methylcytosine; contrariwise, Stresemann and coworkers
reported no effect of EGCG on DNMT activity (2–
50 μmol/L) in cancer cells after a 3-day treatment [5, 94].
It was described that Mg2+ enhances the inhibitory effect
of EGCG on human DNMT activity [5, 95]. In the context
of human cell lines, EGCG (20 μmol/L) inhibits DNMTac-
tivity in oesophageal (KYSE-150), colon (HT-29), prostate
(PC-3), and breast (MCF7 and MDA-MB-231) cancer cells
[2], and also other tumour entities [96–98]. An indirect in-
hibition of DNMT by flavan-3-ols is mediated by an in-
crease in S-adenosyl-L-homocysteine (SAH). This increase
in SAH may be caused by catechol-O-methyltransferase
(COMT) mediated methylation of these flavonoids. Tea
catechin-mediated COMT inhibition was investigated in
the context of rat, mouse, and human liver cytosol [99, 100].
SAH itself, which is formed out of the methyl donor
SAM, is a potent inhibitor of DNMT [5, 101]. EGCG was
found to contribute to the degradation of DNMT3a and
HDAC3 in human HCT 116 colon cancer cells [102].
Interestingly, EGCG treatment of MCF7 and MDA-MB-
231 breast cancer cells resulted in downregulation of hu-
man telomerase reverse transcriptase (hTERT) expression
and thus decreased telomerase levels. As the telomerase is
responsible for lengthening of telomeres in DNA strands,
this enzyme is almost absent in normal cells, whereas it is
considerably expressed in spontaneously immortalized
cells such as cancer cells. Even though tea catechins are
less potent DNMTi than the chemical nucleoside inhibi-
tors, counted as non-nucleoside inhibitors, they could
exert a stable and moderate DNMT inhibition due to
long-term consumption of green tea. Catechins are also
hypothesized to be more gene and tissue specific than the
nucleoside inhibitors, although experimental evidence is
lacking [5, 63]. Sustained consumption of tea may be a
promising cancer-preventive or even cancer-therapeutic
approach [5]. In addition, EGCG modulates cellular HAT
activity and thus histone acetylation and thereby alters the
chromatin structure [50, 103]. EGCG (100 μmol/L) was
found to inhibit the majority of HAT enzymes confirmed
by colourimetric HAT activity assay and in vitro fluorog-
raphy analyses of HAT enzymes [5, 103]. Moreover, EGCG
also modulates miRNA expression in hepatocellular car-
cinoma cells [87], which further contributes to its broad
spectrum of epigenetic activities. Noteworthy, flavan-3-ols
exert further molecular effects, which could contribute to
their inherent anticancer activity, such as inhibition of
dihydrofolate reductase leading to reduced cellular levelsof folic acid [104]. Several in vivo studies investigated the
epigenetic modulation mediated by flavan-3-ols, especially
ECGC, and their impact on cancer formation and tumour
growth. Henning and coworkers showed that substitution
of drinking water with brewed green tea (about 700 mg/L
total green tea catechins) using male severe combined im-
munodeficiency (SCID) mice with human LAPC4 prostate
cancer xenografts [105] resulted in a reduced tumour vol-
ume. The results of the prostate cancer model indicate that
green tea inhibited mRNA and protein expression of
DNMT1 in the tumour cells, which in turn reactivated
antioxidative enzymes [105].
Another interesting study that focuses on colorectal
carcinogenesis in the azoxymethane-ApcMin/+ mouse
model investigated green tea as well. In comparison to
the water control group, administration of green tea so-
lution (0.6 % w/v), as only source of beverage, reduced
the number of newly formed tumours significantly.
Moreover, this study detected a green tea-mediated rise
in protein and transcript levels of retinoid X receptor
alpha (RXRa), which was found to be selectively down-
regulated in intestinal tumours of control mice. Analyses
of CpG sites at the promoter region of the RXRa gene il-
lustrated that consumption of green tea decreased CpG
methylation [106]. Therefore, the authors suggested that
in this in vivo intestinal cancer model, the demethylating
activity of the green tea solution decelerates or even pre-
vents tumourigenesis.
Instead of oral administration, the effects of flavonoids
on tumour formation by topical application were also in-
vestigated by in vivo studies. EGCG in a hydrophilic cream
as vehicle was tested for its antiphotocarcinogenic activity
using a SKH-1 hairless mouse model [107]. Measuring
tumour incidence and tumour size, the topical application
of ECGC displayed a pronounced protection against
photocarcinogenesis [107]. Moreover, the transformation
of papillomas to carcinomas by ultraviolet B (UVB)
seemed to be inhibited by EGCG as well [107].
Despite these promising and interesting findings for
green tea, some studies demonstrated that the demethy-
lating activity is not always detectable in an in vivo situ-
ation. For instance, the oral consumption of green tea
polyphenols (0.3 % in water) by transgenic adenocarcin-
oma of the mouse prostate (TRAMP) mice with an age
of 4 weeks did not affect the DNA methylation of pros-
tate, gut or liver. Moreover, the administration of green
tea polyphenols did not inhibit tumour progression in
this murine prostate model [108, 109].
Flavonols
Flavonols are abundant in vegetables and fruits, among
which onions represent a rich dietary source (Fig. 2).
Other important dietary sources for flavonols include tea,
apples, berries, and wine. Quercetin is the predominant
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extensively investigated compared to most of the other fla-
vonoids [111]. It seems that the glycosylation state of
quercetin strongly influences its intestinal absorption rate
[72]. While both, the glycosides and aglycone of quercetin
are absorbed, the bioavailability of the glycosides is much
better [72]. Due to its long elimination half-life in vivo
[72], daily intake (e.g. 1 week ingestion of a diet rich in
onion) resulted in an accumulation and an increase of
quercetin from 0.04 ± 0.04 μmol/L before to 0.63 ±
0.72 μmol/L [112–114]. Fisetin is found in strawberries,
apples, onions, wine, and tea [46, 115], whereas grapes,
berries, red wine, and tea are sources of myricetin [116, 117]
(Fig. 3). Kaempferol is found in fruits and vegetables such
as tomatoes, hop, red grapes, grapefruit, strawberries,
and Gingko biloba [118] (Fig. 3). The flavonols quercetin,
fisetin, and myricetin were tested for DNMT inhibition and
their IC50 values were determined: quercetin (1.6 μmol/L),
fisetin (3.5 μmol/L), and myricetin (1.2 μmol/L) [2, 95]. All
three flavonols inhibited DNMT1-mediated DNA methyla-
tion in a concentration-dependent manner [95]. Myricetin,
the flavonol exerting the strongest DNMT inhibition, has a
pyrogallol moiety (structurally related to benzene with three
vicinal hydroxy groups) similar to the gallic acid moiety of
EGCG [5, 95]. It has also been shown that the two flavonols
quercetin and fisetin activate sirtuins [5, 80], whereas quer-
cetin (100 μmol/L) seems to drive both HAT activation and
HDAC inhibition determined with a colorimetric activity
assay, which does not distinguish between HAT or HDAC
isoforms [119]. Consistent with these findings, increased
histone H3 acetylation was described after quercetin ex-
posure of leukaemia HL60 cells [50]. Noteworthy, investiga-
tion of the chemopreventive and therapeutic capabilities of
quercetin in a 7,12-dimethylbenz[a]anthracene (DMBA)-
induced hamster buccal pouch (HBP) carcinoma model
showed positive correlation between inhibition of HDAC1
and DNMT1 and anticancer effects exerted by quercetin,
such as induction of cell cycle arrest and apoptosis as well
as inhibition of angiogenesis and invasion. If quercetin
was administered at the same time with DMBA, both the
tumour incidence and the tumour burden were decreased.
Treatment with quercetin after DMBA exposure signifi-
cantly slowed tumour growth [120]. The flavonol kaemp-
ferol exhibits also a distinct inhibitory activity towards
HDAC enzymes. In particular, our group observed a hyper-
acetylation of histone H3 by kaempferol (visualized by
Western blot of hyperacetylated H3 after a 24-h treatment
of human hepatoma cell lines HepG2 and Hep3B as well as
the colon cancer cell line HCT 116). This effect seemed to
depend on inhibition of class I, II, and IV HDAC enzymes
(HDAC1-11) [118]. In addition, reduced cellular viability
and proliferation was demonstrated for HepG2, Hep3B,
and HCT 116 cancer cells after incubation with kaempferol
concentrations that mediated HDACi activity [118].Flavones
Celery, chamomile, and parsley are rich sources of api-
genin [103] (Figs. 2 and 3). Carrots, peppers, celery, olive
oil, peppermint, thyme, rosemary, and oregano are im-
portant dietary sources of luteolin [121] (Fig. 3). Api-
genin and luteolin exert inhibitory effects on 5-cytosine
DNMT as shown, using nuclear extracts of KYSE-510
cells [122]. Both flavones were tested at concentrations
of 20 and 50 μmol/L. Luteolin showed a more pro-
nounced inhibition of DNMT enzymes with an efficacy
of about 50 % at 50 μmol/L, while apigenin only dis-
played a 35 % inhibition at 50 μmol/L [122]. Apigenin
causes cell cycle arrest and apoptosis in human prostate
cancer cells (PC-3 and 22Rv1) [123]. The latter study re-
vealed that apigenin-mediated growth inhibition is due
to inhibition of class I HDAC. The authors showed that
treatment of PC-3 and 22Rv1 cells with 20–40 μmol/L
apigenin inhibited HDAC1 and HDAC3 on mRNA and
protein levels resulting in a global histone H3 and H4
hyperacetylation. Further experiments in a PC-3 xeno-
graft model of athymic nude mice showed that oral in-
take of apigenin at a constant daily dose of 20 or 50 mg
per mouse for 8 weeks inhibited HDAC activity and ex-
pression of HDAC1 and HDAC3 in the cancer tissue
and resulted in reduced tumour growth [123].
Flavanones
Two flavanones tested for epigenetic activity are hesper-
etin and naringenin (Figs. 2 and 3). Flavanones are abun-
dant in the peel of citrus fruits, which are not directly
ingested in significant amounts, and thus the major diet-
ary sources for flavanones are citrus juices [124, 125].
Both hespertin and naringenin inhibit DNMT activity in
nuclear extracts of human oesophageal squamous cell
carcinoma KYSE-510 cells incubated for 1.5 h with 20 or
50 μmol/L. DNMTi activity was not specified for par-
ticular isoforms, and hesperetin was found to be the
more potent inhibitor of both tested flavanones [122].
Isoflavones
Isoflavones are found e.g. in soybeans, fava beans, and
kudzu [87] (Fig. 2). Genistein and daidzein, the most
prominent and well-characterized isoflavones are structur-
ally similar to 17β-oestradiol, which allows their binding
to oestrogen receptors and explains their, albeit weak,
phyto-oestrogenic activity [126–128] (Fig. 3). Regarding
the epigenetic activity of isoflavones, it was demonstrated
that genistein, daidzein, and biochanin A inhibit DNMT
enzymes [5, 122, 129]. Genistein (at concentrations of 2–
20 μmol/L) reduced genomic DNA hypermethylation and
subsequently increased the protein level of retinoic acid
receptor β (RARβ), p16INK4a, and O6-methylguanine DNA
methyltransferase (MGMT) in human KYSE-510 cells
[129]. Further studies confirmed that genistein inhibits
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of silenced tumour suppressor genes [130]. A similar dose-
dependent competitive and non-competitive inhibition of
DNMT by reduction of the cellular availability of SAM
was found with 20–50 μmol/L genistein in oesophageal
squamous cell carcinoma KYSE-150 cells and the prostate
cancer cells lines LNCaP and PC-3 [129]. Interestingly, ge-
nistein represses hTERT expression in breast cancer cells,
paradoxically by promoter demethylation, which is similar
to the activity of ECGC described above [131–133]. The
epigenetic activity of genistein was also assessed in vivo.
Maternal genistein diet of agouti mice during pregnancy
was found to have long-term effects on offspring and al-
tered coat colour due to epigenetic modulation. In this
context it is interesting that prenatal exposure to genistein
(270 mg/kg feed) not only leads to lifelong changes in the
DNA methylation patterns but also has an impact on gene
expression including in the haematopoietic lineage [134].
The epigenetic activity of dietary genistein in timed preg-
nant Sprague-Dawley rats and their male pubs was also in-
vestigated. Genistein was fed either as a soy protein lysate
or purified compound (equivalent to 140 mg/kg genistein
aglycone) and compared to a genistein-free control diet.
Male pubs were injected with the chemical carcinogen
azoxymethane, which decreases levels of acetylated histone
H3. Colon samples were investigated 6 weeks after car-
cinogen injection. In this experimental setting, dietary
genistein modulated the responses of wingless-related in-
tegration site (Wnt) genes by DNA methylation and his-
tone modifications during carcinogen exposure. Thus, it
was suggested that dietary genistein may prevent neoplas-
tic development [135]. This emphasizes that genistein has
multiple effects not only on DNMT enzymes but also on
posttranslational histone modifications like histone demeth-
ylation, HAT activation, and SIRT inhibition [50, 135, 136].
Treatment of MCF7 and MDA-MB-231 breast cancer cells
with genistein (18.5 μmol/L) and daidzein (78.5 μmol/L)
decreased histone trimethylation and increased histone
acetylation of six different genes each responsible for a
protein associated with breast cancer (histone-lysine N-
methyltransferase (EZH2), breast cancer 1, early onset
(BRCA1), oestrogen receptor α (ERα), oestrogen receptor β
(ERβ), nuclear receptor coactivator 3 (SRC-3), and P300)
[137]. Genistein inhibited HDAC activity by 15 % at con-
centrations of 5–20 μmol/L in KYSE-510 cells. Although
genistein is a less potent inhibitor of DNMT than EGCG, it
is more stable in solution and the additional weak HDAC
inhibitory activity of genistein was suggested to result
in comparable gene reactivation as observed for EGCG
[5, 122]. Thus, genistein-mediated gene reactivation may be
based on a synergistic effect of DNMT and HDAC inhib-
ition [5, 138]. Moreover, there is a strong body of evidence
that genistein and other isoflavones regulate miRNA ex-
pression in cancer cells and hence have an impact ontumour growth [87, 133, 139]. Despite the promising pre-
ventive and therapeutic potential of genistein, there is also a
debate on possible deleterious effects by genistein adminis-
tration in the treatment of breast cancer and probably other
hormone dependent cancer entities in humans [140]. An-
other report also described disadvantageous effects of isofla-
vones in regard to increased formation of metastases [141].
Anthocyanidins
Anthocyanidins are responsible for the blue and red col-
ours of plants and are found e.g. in many berries, cherries,
and grapes [72] (Fig. 2). Anthocyanidins are flavonoid
aglycones; their glycosides are called anthocyanins. Well-
known anthocyanidins include cyanidin, delphinidin, mal-
vidin, and pelargonidin, to name only a few. To the best of
our knowledge, the epigenetic activities of the anthocyani-
dins have not yet been investigated.
Flavonolignans
From a chemical point of view, flavonolignans are com-
posed of a flavonoid fused to a lignan (Fig. 2). Silibinin is
the most active flavonolignan and is found e.g. in a stan-
dardized extract from milk thistle known as sylimarin,
which is an antidote used to prevent toxic liver damage
upon ingestion of toxins (e.g. myrocristin-induced tox-
icity in mice, cases of mushroom poisoning in humans)
[142–144] (Fig. 3). Silibinin contains two diastereomers
named silybin A and B [145]. In a model of colon cancer
progression with primary human colon adenocarcinoma
cells SW480 and the corresponding metastatic derivative
SW620, silibinin inhibited DNMT activity in both cell
lines [146]. However, no effect on HDAC activity was
observed, which contrasted with previous reports show-
ing inhibitory effects of silibinin on HDAC enzymes
[147–149]. Lah and coworkers used high concentrations
of silibinin (120 μmol/L and 240 μmol/L, respectively)
for 24 h to treat Huh7 human hepatoma cells and found
significantly increased levels of acetylated histones H3
and H4 [147]. The effect of silibinin on human hepato-
cellular carcinoma xenografts in nude mice was assessed
by Cui and colleagues. After subcutaneous inoculation
of Huh7 cells, mice were treated with vehicle, 80 mg/kg
or 160 mg/kg silibinin per day, respectively. A 5-week
treatment with silibinin resulted in elevated levels of
acetylated histones H3 and H4 in the tumour tissue and
in reduced tumour growth [148]. Similar effects were re-
ported for the non-small cell lung cancer cells H1299
and a corresponding xenograft mouse model (athymic
(nu/nu) male nude mice were subcutaneously injected
with H1299 cells and treated with 100 mg/kg silibinin
per day for 4 weeks) [149]. The authors found in-
hibition of HDAC1, HDAC2, and HDAC3 resulting in
increased levels of acetylated histones H3 and H4.
Promising synergistic effects of silibinin with the well-known
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ported [149].
Conclusions
Epigenetic activities of flavonoids and their impact on
human health
A multitude of biological effects has been reported for fla-
vonoids, including their influence on phase I and II de-
toxifying enzyme activity, antioxidant properties, protein
kinase inhibition, cell cycle regulation, transcriptional, and
epigenetic activities. Flavonoids have attracted increasing
attention due to their diverse health-promoting effects.
Especially the possible chemopreventive and antitumour
activities of flavonoids and other natural compounds are
noteworthy due the fact that cancer incidence and mortal-
ity is globally still exceptionally high [150]. Interestingly,
the cancer incidence varies between the different regions
of the world, and for decades observational studies have
been suggesting that nutritive and lifestyle risk factors
strongly contribute to this discrepancy (Fig. 4) [151–153].
According to this, it was currently estimated that many
cancer-related deaths could be prevented by adequate life-
style modifications, particularly changes in diet or nutri-
tion [12]. The consumption of diets rich in fruits and
vegetables has been consistently associated with a signifi-
cantly reduced risk of cancer development with an impact
on both cancer initiation and progression [87, 154–158].
Importantly, emerging evidence strongly suggests that dietFig. 4 Modulation and interaction of epigenetic mechanisms. Gene regula
modifications and DNA methylation. MiRNA either directly affect gene expr
in general is influenced by several exogenous and endogenous factors inclis a major modulator of the epigenetic state of cells and is
able to reverse abnormal or altered gene expression pat-
terns [87]. This is in line with growing evidence for
sustained remodelling of the human epigenome during
lifetime by nutrition, exercise, mental pressure or stress
and environment (Fig. 4) [159]. The importance of such
acquired epigenetic patterns is supported by observations
in monozygotic twins, where one is affected by several dis-
eases such as diabetes mellitus, while the other remains
unaffected [160]. Young monozygotic twin siblings seem
to be epigenetically relatively similar to each other,
whereas epigenetic changes and a different gene expres-
sion profile were found in aged twin pairs [160]. These dif-
ferences are indicated to depend on environmental factors
such as lifestyle and time spent together [160]. Greatest
changes in DNA methylation patterns were observed in
aged monozygotic twins if they did not share environ-
ments during lifetime [12]. According to epidemiological
studies and dietary interventions in animal models, it was
strongly suggested that nutrition-derived epigenetic modi-
fiers influence the epigenome and even the cancer risk
programming of unborn children in utero [2, 12]. There is
also increasing evidence that maternal malnutrition and
deranged metabolism could have detrimental effects on
offspring (“fetal programming”) and it is very likely that
epigenomes are continuously shaped during lifetime exert-
ing effects also on subsequent generations [12]. Therefore,
dietary factors, including certain flavonoids, may havetion depends on a complex interplay between posttranslational histone
ession or modulate other epigenetic mechanisms. Epigenetic activity
uding nutrition
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epigenome and other modes of action. Representatives of
the flavonoid subclasses flavan-3-ols (catechin and EGCG),
flavonols (kaempferol, quercetin, myricetin, and fisetin),
flavones (apigenin and luteolin), flavanones (hesperetin
and naringenin), isoflavones (genistein and daidzein), and
the flavonoid-related class of flavonolignans (silibinin) have
been reviewed above focusing on DNA methylation and
histone acetylation [2, 5, 95, 122, 146]. As flavonoids are
present in fruits, vegetables, and tea, a short overview of
food containing high amounts of these epigeneticallyTable 1 Food containing high amounts of epigenetically active flav
Description Class Flavonoid











Soybeans, mature seeds, raw (all sources) Isoflavones Daidzein
Genistein
Spices, parsley, dried (Petroselinum crispum) Flavones Apigenin
Luteolin






Cacao beans Flavan-3-ols (+)-Catechin
(−)-Epicatechin











Flavonoid and isoflavone content are summarized in the USDA databases cited belo
aBhagwat, S., Haytowitz, D.B. Holden, J.M. (Ret.). 2013. USDA Database for the Flavo
Agricultural Research Service. Nutrient Data Laboratory Home Page: http://www.ars
bBhagwat, S., Haytowitz, D.B. Holden, J.M. 2008. USDA Database for the Isoflavone C
Agricultural Research Service, Nutrient Data Laboratory Home Page: http://www.arsactive flavonoids is depicted in Table 1. Nonetheless, it re-
mains controversial if e.g. long-term exposure to “epigenetic
diets” rich in flavonoids or flavonoid supplements could
also induce unwanted effects due to their lack of specifi-
city regarding distinct isoforms of enzymes responsible for
epigenetic modulation like HAT and HDAC [12]. Low
specificity was found to limit the clinical application of
epigenetic drugs like HDACi, and despite their epigenetic
activity, flavonoids target a multiplicity of other pharmaco-
logical pathways. On the one hand, these pleiotropic ef-
fects such as inhibition of angiogenesis, inflammatoryonoids
Ǿ mg/100 g Sources of data
1.50 aUSDA Database for the Flavonoid Content of




0.24 aUSDA Database for the Flavonoid Content of





62.07 bUSDA Database for the Isoflavone Content of
Selected Foods: e.g. [197–202]
80.99




0.49 aUSDA Database for the Flavonoid Content of
Selected Foods: e.g. [204, 205]
0.35
0.46
88.45 aUSDA Database for the aFlavonoid Content of
Selected Foods: e.g. [206]
99.18
1.51 aUSDA Database for the Flavonoid Content of











noid Content of Selected Foods, Release 3.1. U.S. Department of Agriculture,
.usda.gov/News/docs.htm?docid=6231
ontent of Selected Foods, Release 2.0. U.S. Department of Agriculture,
.usda.gov/News/docs.htm?docid=6382
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beneficial for the treatment of several diseases and in par-
ticular cancer where most of mono-therapeutic efforts are
non-satisfying [163, 164]. On the other hand, there is also
a risk to induce unwanted side effects, and there is little
knowledge about their bioavailability (e.g. aglycones and
glycosides), metabolism, and in particular about their bio-
activity and the fate of arising metabolites. Moreover,
many clinicians are generally incredulous towards phyto-
chemicals in the treatment of life-threatening diseases,
and appropriate animal studies and clinical studies with
flavonoids are still very limited. In terms of cancer treat-
ment, oncologists are sceptical towards the antioxidant ef-
fects exerted by flavonoids, especially when combined with
classical cytostatic drugs. It is still not clear if antioxidant
properties are a problematic issue during chemotherapy.
Generally, the use of flavonoids especially at super-
physiological doses as conducted in several in vitro studies
has to be carefully evaluated for the in vivo situation.
Moreover, most flavonoids and other polyphenols with
epigenetic activity in vitro have not yet been tested in ani-
mal models, and when tested, only a few epigenetic marks
have been analysed in depth. In addition, the overall func-
tional relevance of epigenetic modulation exerted by flavo-
noids and other natural compounds in chemoprevention
and chemotherapy has to be further elucidated [165].
According to these uncertainties and hindrances, the dis-
cussion on epigenetic modulation by flavonoids and their
impact on human health remains highly controversial and
gives a possible explanation for the missing breakthrough
of these natural compounds in clinical use [166–171].
Intake of flavonoids and cancer risk
According to the currently available data, the intake of a
balanced diet is strongly recommended for maintaining
health and for the prevention of a broad spectrum of
“Western civilization” diseases like cancer. Current stud-
ies reveal that malnutrition and obesity are under-
recognized, but are important risk factors for cancer,
cancer recurrence, and cancer-related mortality. More-
over, obesity negatively affects treatment outcome as
well as prognosis of cancer patients [172]. Due to the
significantly increased prevalence of obesity on a global
scale, nutrition and lifestyle have become important as-
pects of cancer prevention and therapy. Therefore, many
phytochemicals and/or their respective metabolites de-
rived from fruits, vegetables or nutrients are currently
analysed for their potential beneficial effects on health.
In this respect especially, flavonoids as a large group of
secondary plant metabolites have been under extensive
investigation for decades [72]. Importantly, it has been
controversially discussed if flavonoids exert any protec-
tion against cancer in humans. Epidemiological studies
found conflicting results with respect to the effects offlavonoid intake and cancer incidence and mortality. For
pancreatic cancer, a large prospective study with an analytic
cohort of 537,104 persons found no evidence that flavo-
noids have a protective role in carcinogenesis (hazard ratio
(HR) = 1.09) [173]. Another large prospective study with
a cohort of 477,312 men and woman recruited in 10
European countries also found no association between total
flavonoid intake and bladder cancer risk [174]. In contrast,
some experimental data suggest that specific flavonoids
could even promote tumour formation in certain subsets of
patients. A randomized placebo-controlled study on female
patients illustrated that the supplementation of soy, which
contains high amounts of isoflavones, may upregulate genes
that drive cell cycle and proliferation pathways and there-
fore could adversely affect breast carcinogenesis [175]. In
this regard, a large prospective cohort study with a multi-
ethnic population of 84,450 women examined the potential
connection of dietary isoflavone intake and overall breast
cancer risk. Interestingly, no statistically significant associ-
ation between dietary isoflavone intake and overall breast
cancer risk was found (HR = 0.96) [176]. In the same study,
some ethnic groups benefited from a high isoflavone intake
and had a reduced risk in breast cancer incidence, which is
in line with a meta-analysis of corresponding prospective
studies (relative risk (RR) = 0.89 on average with RR = 0.76
for Asian women and only RR = 0.97 for Western women)
[177]. Although the impact of specific flavonoids on
particular tumour entities is discussed controversially in
the literature, the overall evidence suggests that flavonoids
rather protect from cancer.
Referring to this, the cancer-preventive potential of
dietary flavonoids was recently reviewed by Romagnolo
and Selmin [178]. Epidemiological studies suggest that
flavonoid ingestion reduces the risk of versatile cancer
entities like pancreas, prostate, lung, colon, breast, and
prostate cancer even though results are sometimes in-
conclusive [178]. It is challenging to construe data ob-
tained from epidemiological studies because the majority
are case-control or retrospective studies and less pro-
spective trials, respectively [178].
In this regard, a prospective study involving 9959 men
and women observed a reduction in lung cancer cases
associated with increased flavonoid intake over a period
of 24 years (RR = 0.54) [179].
Focusing on the subclasses of flavonoids, in an Italian
case-control study with about 10,000 cancer patients and
16,000 controls, the risk to develop oral or laryngeal can-
cer was inversely related to the intake of total flavonoids
(odds ratio (OR) = 0.56 and 0.60, respectively), flavanones
(OR = 0.51 and 0.60, respectively), and flavonols (OR =
0.62 and 0.32, respectively) [178, 180]. Comparable results
for laryngeal cancer were reported for flavanones (OR =
0.60), flavan-3-ols (OR = 0.64), and flavonols (OR = 0.32)
[181], whereas no association was found for isoflavones,
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mainly by consumption of citrus fruits reduced oesophageal
cancer risk (OR = 0.38) [178, 182]. Protective effects against
gastric cancer were reported for quercetin and EGCG
[183, 184], whereas an increased risk for higher isoflavone
intake was described in Japanese women simultaneously
using exogenous hormones [185]. Total flavonol and par-
ticularly kaempferol intake was reported to reduce the risk
of pancreatic cancer (OR = 0.78) [186].
In line, the large prospective study of Zamora-Ros and
colleagues suggested a protective association between
dietary intake of flavonols and the risk of bladder cancer
(HR = 0.74) [174]. Two large studies analysing the risk of
epithelial ovarian cancer concluded that several flavo-
noids and in particular flavonols seem to be associated
with a reduced risk of ovarian cancer (HR = 0.85 for total
flavonoids and RR = 0.75 for the combined intake of
myricetin, kaempferol, quercetin, luteolin, and apigenin)
[187, 188]. For isoflavones (another subclass of flavo-
noids), a randomized placebo-controlled trial displayed
that uptake of isoflavones could reduce the prostate can-
cer risk [189]. These results are in line with the observa-
tion that supplementation of isoflavonoids seems to
diminish the increase of serum prostate-specific antigen
(PSA) in men following local therapy [190]. Even though
there are obvious study limitations based on diet and
lifestyle variables, several trials detected an association
between dietary intake of specific flavonoids or flavonoid
subclasses and reduced occurrence of certain cancer
types. The molecular mechanisms underlying the anti-
cancer properties of flavonoids are numerous and in-
clude the modulation of cellular signalling pathways,
direct and indirect antioxidant activities, and epigenetic
phenomena. The latter are important for tumour forma-
tion and growth and thus also for cancer prevention and
therapy. Flavonoids are epigenetically active both in vitro
and in vivo, albeit very high and often non-physiological
concentrations have been used in experiments to in-
vestigate their epigenetic activities. Nevertheless, some
flavonoids, such as quercetin, accumulate in blood and
tissues over time [72, 112] and may thus reach suffi-
ciently high concentrations to exert epigenetic activity.
Furthermore, flavonoids may act synergistically with
each other, with other natural compounds present in the
diet and/or with synthetic drugs, and may thereby facili-
tate changes to the epigenome at low concentrations
[191]. Nonetheless, low bioavailability of flavonoids is a
crucial issue (due to restricted intestinal digestive and ab-
sorptive dynamics, metabolism by the intestinal microflora
and after absorption) [5, 192]. Further in-depth research
and prospective as well as mechanistic studies are required
to investigate the beneficial effects of the different fla-
vonoids in detail. Based on these data, simple changes in
diet and food intake could contribute to prevention andtreatment of human diseases including cancer. Safe,
effective, and especially pleiotropic chemopreventive com-
pounds are urgently needed considering the fact that can-
cers often exhibit long latencies of about 20 years and that
detrimental changes in malignant cells should be counter-
acted as early as possible [12]. Many flavonoids and other
polyphenols seem to regulate multiple targets e.g. involved
in cancer-inflammation and could therefore be low priced,
easily available, and highly tolerable compounds, and
long-term exposure at physiological concentrations could
shape the epigenome in a desirable and cumulative man-
ner [12]. Despite the promising results for diets rich in
fruit and vegetables in terms of disease prevention, it re-
mains unclear if additional supplementation with isolated
flavonoids would have significant additional beneficial
health effects in humans. Clearly, pharmacological drugs
are inevitably required for cancer therapy, but it seems
that flavonoids and other natural compounds could con-
tribute to future treatment strategies.
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